OSI Pharmaceuticals discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally.
Now I'm just a fish and don't know the first thing about molecular targeted therapies but here's what I do know:
The biotechnology sector has a strong back wind and great interest in the sector's potential.
2. This company has a return on equity of 149% !!
3. Quarterly earnings growing 340% !!
4. positive cash flow and 17% revenue growth.
And all this rapped up in a very affordable P/E of 29..
It seems like the company is being run well and I'm up 13% in the worst month in decades..
put this company on your radar.. I suspect more good news is on the way.
- Post a new opinion
- Recently Posted
- Private Notes
- Portfolio
- Portfolio Watchlist
- Gurus
- Track List
- My Opinions
Top 1%